RG
SCMP

Renaissance Group’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Renaissance Group’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-22,723
Closed -$308K – 314
2016
Q4 		$308K Sell
22,723
-444
-2% -$6.19K 0.01% 242
2016
Q3 		$285K Buy
+23,167
New +$273K 0.01% 230

Other funds holding SCMP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Group's SCMP Position: Q1 2017 in Review

Renaissance Group sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2017, closing a stake of 22,723 shares — an estimated $308K sold.

Renaissance Group first reported a position in SCMP in Q3 2016 and held it in 2 quarters. The position peaked at $308K in Q4 2016. 167 funds tracked by Wall St. Rank hold SCMP as of Q1 2017.

  • Renaissance Group reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Renaissance Group sold 22,723 Sucampo Pharmaceuticals, Inc. shares in Q1 2017, an estimated $308K.
  • Renaissance Group first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2016 and held it in 2 quarters.
  • Renaissance Group's Sucampo Pharmaceuticals, Inc. position peaked at $308K in Q4 2016.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2017.

Based on Renaissance Group's 13F filing for Q1 2017, filed 3 May 2017.